Athena Athena

X
[{"orgOrder":0,"company":"Anew Medical","sponsor":"Redwoods Acquisition Corp.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anew Medical, Inc. Enters Into Definitive Merger Agreement with Redwoods Acquisition Corp.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Anew Medical

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ANEW intends to use the proceeds from the transaction to progress its lead gene therapy programs including, Alpha Klotho-based gene therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).

            Lead Product(s): Alpha Klotho-based Gene Therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Redwoods Acquisition Corp.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger May 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY